Krystn leads Grant Thornton’s valuation practice in New York and life science valuation practice nationally. She has over 17 years of experience advising clients on valuations, transactions and tax restructurings, including acquisitions, divestitures, spin-offs, and intellectual property migrations. Her pharmaceutical and life sciences experience spans across industry subsectors, including big pharma, biotech, medical device/diagnostics, generic, specialty, animal health, OTC/consumer, and services, with transaction sizes ranging from $25 million to in excess of $70 billion.

Prior to joining Grant Thornton, Krystn worked as a healthcare investment banker focused on strategic M&A at Stifel, via its acquisition of Torreya Capital, advising on transactions across generics, specialty pharma, complex formulations, and infectious disease. Previously, Krystn was a Director in PwC's Deals practice focused on life sciences, and also was the director lead for the firm's middle market clients and opportunities business development initiative for the sector in the New York metro region.

She is a licensed CPA in the State of New York, a CFA Charterholder and holds inactive Series 63 and 79 FINRA licenses in good standing. Krystn holds BSM Finance and Masters of Accountancy degrees from Tulane University’s A.B. Freeman School of Business. She resides in Manhattan with her husband and is an avid ballet supporter, serving on the Education Committee for American Ballet Theatre’s Jacqueline Kennedy Onassis School, and having previously served as Treasurer and Audit Committee Chair on the Board of Trustees for Youth America Grand Prix, an international ballet scholarship competition.